Programmed death-1 is a marker for abnormal distribution of naive/memory T cell subsets in HIV-1 infection

Journal of Immunology

Volumn 191, Issue 5, 2013, Pages 2194-2204

  Breton, Gaëlle ^a,b   Chomont, Nicolas ^a,b,c   Takata, Hiroshi ^c   Fromentin, Rémi ^c   Ahlers, Jeffrey ^c   Filali Mouhim, Abdelali ^c   Riou, Catherine ^a,b   Boulassel, Mohamed Rachid ^d   Routy, Jean Pierre ^d,e   Yassine Diab, Bader ^a,b   Sékaly, Rafick Pierre ^a,b,c,e  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c Vaccine and Gene Therapy Institute of Florida   (United States)

^d ROYAL VICTORIA HOSPITAL   (Canada)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN BCL 2; RITONAVIR; STAVUDINE; ZIDOVUDINE;

ACUTE DISEASE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MATURATION; CELL METABOLISM; CELL PROLIFERATION; CHRONIC DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; DRUG EFFECT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MEMORY T LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENESCENCE; T LYMPHOCYTE SUBPOPULATION; UPREGULATION; VIRUS LOAD;

BIOLOGICAL MARKERS; FLOW CYTOMETRY; HIV INFECTIONS; HUMANS; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTE SUBSETS;

EID: 84883354823     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1200646     Document Type: Article

References (53)

1. Brenchley, J. M., D. A. Price, T. W. Schacker, T. E. Asher, G. Silvestri, S. Rao, Z. Kazzaz, E. Bornstein, O. Lambotte, D. Altmann, et al. 2006. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 12: 1365-1371.
2. + T cell levels: results of 6 years of follow-up. The Los Angeles Center, Multicenter AIDS Cohort Study. J. Acquir. Immune Defic. Syndr. 6: 904-912.
3. + cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 16: 83-92.
4. + T-cell activation in HIV infection is antigenic stimulation. J. Acquir. Immune Defic. Syndr. 25: 203-211.
5. Hazenberg, M. D., J. W. Stuart, S. A. Otto, J. C. Borleffs, C. A. Boucher, R. J. de Boer, F. Miedema, and D. Hamann. 2000. T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). Blood 95: 249-255.
6. Sousa, A. E., J. Carneiro, M. Meier-Schellersheim, Z. Grossman, and R. M. Victorino. 2002. CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J. Immunol. 169: 3400-3406.
7. Gougeon, M. L. 2005. To kill or be killed: how HIV exhausts the immune system. Cell Death Differ. 12(Suppl 1): 845-854.
8. Kedzierska, K., and S. M. Crowe. 2001. Cytokines and HIV-1: interactions and clinical implications. Antivir. Chem. Chemother. 12: 133-150.
9. + T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol. 2: E20.
10. + T cells and their association with HIV-1-induced T cell dysfunction. J. Immunol. 175: 8415-8423.
11. + CTLs ex vivo. J. Immunol. 168: 5954-5958.
12. Giorgi, J. V., L. E. Hultin, J. A. McKeating, T. D. Johnson, B. Owens, L. P. Jacobson, R. Shih, J. Lewis, D. J. Wiley, J. P. Phair, et al. 1999. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J. Infect. Dis. 179: 859-870.
13. Hazenberg, M. D., S. A. Otto, B. H. van Benthem, M. T. Roos, R. A. Coutinho, J. M. Lange, D. Hamann, M. Prins, and F. Miedema. 2003. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 17: 1881-1888.
14. + T cell activation is associated with low susceptibility to HIV-1 infection. J. Immunol. 175: 6117-6122.
15. Zeng, M., A. J. Smith, S. W. Wietgrefe, P. J. Southern, T. W. Schacker, C. S. Reilly, J. D. Estes, G. F. Burton, G. Silvestri, J. D. Lifson, et al. 2011. Cumulative mechanisms of lymphoid tissue fibrosis and T cell depletion in HIV-1 and SIV infections. J. Clin. Invest. 121: 998-1008.
16. + T-cell activation and depletion in human immunodeficiency virus type 1 infection: type I interferonmediated disruption of T-cell dynamics. J. Virol. 82: 1870-1883.
17. Smith, A. J., Q. Li, S. W. Wietgrefe, T. W. Schacker, C. S. Reilly, and A. T. Haase. 2010. Host genes associated with HIV-1 replication in lymphatic tissue. J. Immunol. 185: 5417-5424.
18. Douek, D. C., L. J. Picker, and R. A. Koup. 2003. T cell dynamics in HIV-1 infection. Annu. Rev. Immunol. 21: 265-304.
19. Douek, D. C. 2003. Disrupting T-cell homeostasis: how HIV-1 infection causes disease. AIDS Rev. 5: 172-177.
20. Munier,M. L., and A. D. Kelleher. 2007. Acutely dysregulated, chronically disabled by the enemy within: T-cell responses to HIV-1 infection. Immunol. Cell Biol. 85: 6-15.
21. Dion, M. L., J. F. Poulin, R. Bordi, M. Sylvestre, R. Corsini, N. Kettaf, A. Dalloul, M. R. Boulassel, P. Debré, J. P. Routy, et al. 2004. HIV infection rapidly induces and maintains a substantial suppression of thymocyte proliferation. Immunity 21: 757-768.
22. Douek, D. C., R. D. McFarland, P. H. Keiser, E. A. Gage, J. M. Massey, B. F. Haynes, M. A. Polis, A. T. Haase, M. B. Feinberg, J. L. Sullivan, et al. 1998. Changes in thymic function with age and during the treatment of HIV infection. Nature 396: 690-695.
23. Schacker, T. W., P. L. Nguyen, G. J. Beilman, S. Wolinsky, M. Larson, C. Reilly, and A. T. Haase. 2002. Collagen deposition in HIV-1 infected lymphatic tissues and T cell homeostasis. J. Clin. Invest. 110: 1133-1139.
24. + effector memory insufficiency and overt disease in chronic SIV infection. J. Exp. Med. 204: 2171-2185.
25. Rethi, B., C. Fluur, A. Atlas, M. Krzyzowska, F. Mowafi, S. Grützmeier, A. De Milito, R. Bellocco, K. I. Falk, E. Rajnavölgyi, and F. Chiodi. 2005. Loss of IL-7Ra is associated with CD4 T-cell depletion, high interleukin-7 levels and CD28 down-regulation in HIV infected patients. AIDS 19: 2077-2086.
26. Greenwald, R. J., G. J. Freeman, and A. H. Sharpe. 2005. The B7 family revisited. Annu. Rev. Immunol. 23: 515-548.
27. Pentcheva-Hoang, T., L. Chen, D. M. Pardoll, and J. P. Allison. 2007. Programmed death-1 concentration at the immunological synapse is determined by ligand affinity and availability. Proc. Natl. Acad. Sci. USA 104: 17765-17770.
28. Freeman, G. J., A. J. Long, Y. Iwai, K. Bourque, T. Chernova, H. Nishimura, L. J. Fitz, N. Malenkovich, T. Okazaki, M. C. Byrne, et al. 2000. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192: 1027-1034.
29. + T cells and is overcome by IL-2. Eur. J. Immunol. 32: 634-643.
30. + T cells leads to reversible immune dysfunction. Nat. Med. 12: 1198-1202.
31. Day, C. L., D. E. Kaufmann, P. Kiepiela, J. A. Brown, E. S. Moodley, S. Reddy, E. W. Mackey, J. D. Miller, A. J. Leslie, C. DePierres, et al. 2006. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443: 350-354.
32. + T cell survival in HIV infection. J. Exp. Med. 203: 2281-2292.
33. + T cells is driven by viral replication and associated with T cell dysfunction. J. Immunol. 179: 1979-1987.
34. + T-cell exhaustion in typical progressors but not in long-term nonprogressors. Blood 109: 4671-4678.
35. Velu, V., K. Titanji, B. Zhu, S. Husain, A. Pladevega, L. Lai, T. H. Vanderford, L. Chennareddi, G. Silvestri, G. J. Freeman, et al. 2009. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 458: 206-210.
36. + T cells. J. Immunol. 178: 788-797.
37. Miller, J. D., D. Masopust, E. J. Wherry, S. Kaech, G. Silvestri, and R. Ahmed. 2005. Differentiation of CD8 T cells in response to acute and chronic viral infections: implications for HIV vaccine development. Curr. Drug Targets Infect. Disord. 5: 121-129.
38. Gamberg, J., I. Pardoe, M. I. Bowmer, C. Howley, and M. Grant. 2004. Lack of CD28 expression on HIV-specific cytotoxic T lymphocytes is associated with disease progression. Immunol. Cell Biol. 82: 38-46.
39. + T cells vary in differentiation phenotype in different persistent virus infections. Nat. Med. 8: 379-385.
40. + T cells. Blood 101: 2711-2720.
41. Shen, T., J. Zheng, C. Xu, J. Liu, W. Zhang, F. Lu, and H. Zhuang. 2010. PD-1 expression on peripheral CD8+ TEM/TEMRA subsets closely correlated with HCV viral load in chronic hepatitis C patients. Virol. J. 7: 310.
42. + Treg cells in chronic HCV infected-patients. Virol. J. 8: 279.
43. Rosignoli, G., C. H. Lim, M. Bower, F. Gotch, and N. Imami. 2009. Programmed death (PD)-1 molecule and its ligand PD-L1 distribution among memory CD4 and CD8 T cell subsets in human immunodeficiency virus-1-infected individuals. Clin. Exp. Immunol. 157: 90-97.
44. Salisch, N. C., D. E. Kaufmann, A. S. Awad, R. K. Reeves, D. P. Tighe, Y. Li, M. Piatak, Jr., J. D. Lifson, D. T. Evans, F. Pereyra, et al. 2010. Inhibitory TCR coreceptor PD-1 is a sensitive indicator of low-level replication of SIV and HIV- J. Immunol. 184: 476-487.
45. Lin, S. J., C. D. Peacock, K. Bahl, and R. M. Welsh. 2007. Programmed death-1 (PD-1) defines a transient and dysfunctional oligoclonal T cell population in acute homeostatic proliferation. J. Exp. Med. 204: 2321-2333.
46. Kinter, A. L., E. J. Godbout, J. P. McNally, I. Sereti, G. A. Roby, M. A. O'Shea, and A. S. Fauci. 2008. The common γ-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J. Immunol. 181: 6738-6746.
47. Shankar, E. M., K. F. Che, D. Messmer, J. D. Lifson, and M. Larsson. 2011. Expression of a broad array of negative costimulatory molecules and Blimp-1 in T cells following priming by HIV-1 pulsed dendritic cells. Mol. Med. 17: 229-240.
48. Barber, D. L., E. J. Wherry, D. Masopust, B. Zhu, J. P. Allison, A. H. Sharpe, G. J. Freeman, and R. Ahmed. 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439: 682-687.
49. Douek, D. C., M. R. Betts, B. J. Hill, S. J. Little, R. Lempicki, J. A. Metcalf, J. Casazza, C. Yoder, J. W. Adelsberger, R. A. Stevens, et al. 2001. Evidence for increased T cell turnover and decreased thymic output in HIV infection. J. Immunol. 167: 6663-6668.
50. Abrahams, M. R., J. A. Anderson, E. E. Giorgi, C. Seoighe, K. Mlisana, L. H. Ping, G. S. Athreya, F. K. Treurnicht, B. F. Keele, N. Wood, et al; CAPRISA Acute Infection Study Team; Center for HIV-AIDS Vaccine Immunology Consortium. 2009. Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants. J. Virol. 83: 3556-3567.
51. Fischer, W., V. V. Ganusov, E. E. Giorgi, P. T. Hraber, B. F. Keele, T. Leitner, C. S. Han, C. D. Gleasner, L. Green, C. C. Lo, et al. 2010. Transmission of single HIV-1 genomes and dynamics of early immune escape revealed by ultra-deep sequencing. PLoS ONE 5: e12303.
52. Grabmeier-Pfistershammer, K., P. Steinberger, A. Rieger, J. Leitner, and N. Kohrgruber. 2011. Identification of PD-1 as a unique marker for failing immune reconstitution in HIV-1-infected patients on treatment. J. Acquir. Immune Defic. Syndr. 56: 118-124.
53. Kline, J., and T. F. Gajewski. 2010. Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer. Curr. Opin. Investig. Drugs 11: 1354-1359.